Bayer Launches Eylea (aflibercept) Pre-Filled Syringe in Europe

Shots:

• The EMA has approved Bayer’s Eylea® (aflibercept) injection pre-filled syringe with the EC’s decision applies to all 27 EU member states as well as the UK, Iceland, Norway and Liechtenstein
• The P-IV ALTAIR study assessing Eylea (aflibercept) with T&E dosing regimens in patients with wet AMD, demonstrated a reduction in injection burden, i.e. up to 60% patients were able to achieve injection intervals of @3mos. (12wks. interval) or >40% achieved injection intervals of 4mos.(16wks. interval)
• Eylea is a VEGF inhibitor targeting VEGF-A and PLGF, formulated as an injection for the eye, act by blocking the growth of new blood vessels and by decreasing vascular permeability in the eye and is approved therapy for wet AMD, macular edema following RVO, DME and myopic CNV

Click here ­to­ read full press release/ article | Ref: Bayer | Image: Pinterest